Table 5. Analyses of cost-effectiveness according to vaccination strategy.
| Strategies | Cost per patient | Incremental cost | Effectiveness per patient | Incremental effectiveness per patient | ICER* |
|---|---|---|---|---|---|
| $ | $ | QALY | QALY | $/QALY | |
| No vaccination | 53.71 | - | 12.2000 | - | - |
| PPSV23 for elderly aged ≥65 y (vaccine uptake rate of 60%) | 56.53 | 2.83 | 12.2001 | 0.00011 | 25,786 |
| PCV13 for elderly aged ≥65 y (vaccine uptake rate of 60%) | 58.19 | 4.48 | 12.2010 | 0.00099 | 4,529 |
| PPSV23 for elderly aged ≥65 y (vaccine uptake rate of 80%) | 56.82 | 3.12 | 12.2002 | 0.00018 | 17,354 |
| PCV13 for elderly aged ≥65 y (vaccine uptake rate of 80%) | 59.27 | 5.55 | 12.2010 | 0.0011 | 5,045 |
| Current strategy† | 56.53 | - | 12.2000 | - | - |
| PCV13 for elderly aged ≥65 y (vaccine uptake rate of 60%) | 57.10 | 0.56 | 12.2008 | 0.0007 | 797 |
| PCV13 for elderly aged ≥65 y (vaccine uptake rate of 80%) | 57.17 | 0.63 | 12.2010 | 0.0009 | 701 |
| Sequential PCV13-PPSV23 for elderly aged ≥65 y (vaccine uptake rate of 60%) |
57.14 | 0.61 | 12.2005 | 0.0005 | 1,228 |
| Sequential PCV13-PPSV23 for elderly aged ≥65 y (vaccine uptake rate of 80%) |
59.73 | 3.19 | 12.2003 | 0.0003 | 10,645 |
* ICER: incremental cost-effectiveness ratio ($/QALY gained)
†Current strategy: PPSV23 vaccination for elderly aged ≥65 years with a targeted uptake rate of 60%